ADM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Archer-Daniels-Midland Co is not a strong buy for a beginner, long-term investor at this time. The stock lacks significant positive momentum, and recent financial performance shows declining revenue, net income, and EPS. While there are some positive catalysts, such as a joint venture in animal nutrition and a dividend increase, these are overshadowed by weak technical indicators, neutral trading sentiment, and mixed analyst ratings. A hold position is recommended until stronger growth signals or a more favorable entry point emerge.
The MACD histogram is negative and expanding, RSI is neutral at 42.181, and moving averages are converging, indicating no clear trend. The stock is trading below the pivot level of 68.071, with key support at 66.463 and resistance at 69.679.
Joint venture with Alltech in animal nutrition, which could enhance market competitiveness.
Dividend increase to $0.52 per share.
Barclays raised the price target to $68.
SEC settlement and restatement of 2023 and 2024 filings, which could impact investor confidence.
Declining financial performance in Q4 2025, with revenue, net income, and EPS all dropping significantly.
Mixed analyst ratings, with several firms maintaining neutral or underperform ratings.
In Q4 2025, revenue dropped by -13.68% YoY to $18.56 billion, net income fell by -19.58% YoY to $456 million, and EPS declined by -20.34% YoY to $0.94. However, gross margin improved slightly to 6.54%, up 3.48% YoY.
Analyst sentiment is mixed. Barclays raised its price target to $68 with an Equal Weight rating, while JPMorgan and BofA maintain underweight and underperform ratings, citing concerns about weaker margins and mixed agricultural outlooks. The price target range is between $50 and $68.
